만성 폐쇄성 폐 질환 (COPD) Diagnosis 시장 규모 및 점유율 분석 - 성장 추세 및 예측 (2024 - 2031)
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market은 Diagnosis Method (linical Assessment, Imaging Techniques, Laboratory Test)에 의해 분류됩니다. Severity-Based Diagnosis (GOLD 1–4 Classification, Group A–D Classification), Molecule Type (Monoclonal Antibody, Peptides, Polymer, Small Molecular, Gene Therapy), By Product (Mono, Combination, Mono/Combination, Europe), Asia, Asia, Asia, Asia, Asia, Asia, Asia, Asia, Asia, Asia, Asia, Asia, Korea, Asia, Korea, Korea, Korea, Korea. 보고서는 상기 언급 된 값 (USD 억)을 제공합니다.
Competitive overview of 만성 폐쇄성 폐 질환 (COPD) Diagnosis 시장
만성 폐쇄성 폐 질환 (COPD)에서 작동하는 주요 선수 진단 시장은 GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceuticals, Pfizer, Merck, Sanofi, Mylan 및 Sun Pharmaceutical Industries를 포함합니다.
만성 폐쇄성 폐 질환 (COPD) Diagnosis 시장 Leaders
- 글리코SmithKline (GSK)
- 카테고리
- Boehringer 인젤하임
- 인기 카테고리
- Teva 제약
*Disclaimer: Major players are listed in no particular order.
만성 폐쇄성 폐 질환 (COPD) Diagnosis 시장 - Competitive Rivalry, 2023
만성 폐쇄성 폐 질환 (COPD) Diagnosis 시장
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights